Table 2. IC₅₀ values^a of integrin Ab-, FK-, sITG- and peptide-mediated blocking of MAdV and chimeric HAdV reporter infection.

Cell type / mean fluorescence intensity (MFI) of staining with indicated control and integrin antibodies	MOI	Blocking Agent b	M1-IX-G	H5-ΔE3B-CG-FK-M1	M3-IX-G	H5-ΔE3B-CG-FK-M3	M2-ΔE1A-G	H5-ΔE3B-CG
CMT93 mouse colon cancer / con Ab: 304 anti-β6: 4,599 anti-β8: 357	1	Ab-β6	124	138	95	119	>800	>800
	1	Ab β8	>800	>800	>800	>800	>800
	1	FK-M1	4.8	5.6	3.5	5.4	> 800
	1	FK-M3	3.6	4.1	2.1	3.5	> 800	> 800
	1	FK-H5	>800	>800	>800	>800	>800	22
	1	sITG mαvβ3	>800		>800
	1	sITG mαvβ6	80		59
	1	sITG mαvβ8	>800		>800
	1	sITG hαvβ6	83		52
	1	sITG hαvβ8	>800		>800
	1	A20FMDV2	6.3	4.7	1.1		>5,000
	1	A20FMDV2-E	>5,000	>5,000	3,770		> 5000
	1	A20M1	26	30	5.3		> 5000
	1	A20M3	7.4		1.3
B16-mβ6 mouse melanoma / con Ab: 142 anti-β6: 3,992 anti-β8: 150	3	Ab-β6	150	551	124	201
	3	Ab-β8	>800	>800	>800	>800	>800
B16-m β8 / con Ab: 123 anti-β6: 130 anti-β8: 3,561	3	Ab-β6	>800	>800	>800	>800
	3	Ab-β8	61	95	17	75
M000216 human melanoma / con Ab: 219 anti-β6: 259 anti-β8: 9,052	3	Ab β6	>800	>800	>800	>800		>800
	3	Ab β8	73	120	13	64		>800
	3	FK-M1	393		112
	3	FK-M3	116		68
	3	FK-H5	>800		>800
	3	sITG mαvβ3	>800		>800
	3	sITG mαvβ6	11		4.5
	3	sITG mαvβ8	>800		>800
	3	sITG hαvβ6	7.6		2.3
	3	sITG hαvβ8	>800		>800
	3	A20FMDV2	898		165
	3	A20M1	~5,000		150
	3	A20M3	422		17.9
A549-hβ6 human lung carcinoma con Ab: 219 anti-β6: 1,349 anti-β8: 220	3	A20FMDV2	110
	3	A20M1	336

^a Data correspond to blocking experiments shown in Figs 2 and 6 and S4, S8, S9 and S11, respectively.

^b IC₅₀ concentrations of antibodies, FKs and sITGs are in ng/ml; concentration of peptides are in nM